{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.93","value":"2.3"},{"groupId":"OG001","spread":"11.50","value":"-7.5"},{"groupId":"OG002","spread":"15.87","value":"-3.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"80"}],"units":"Participants"}],"title":"Sitting pulse Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.05","value":"-1.8"},{"groupId":"OG001","spread":"18.07","value":"-2.6"},{"groupId":"OG002","spread":"17.46","value":"-2.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"53"}],"units":"Participants"}],"title":"Sitting pulse Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.39","value":"2.9"},{"groupId":"OG001","spread":"15.46","value":"3.7"},{"groupId":"OG002","spread":"15.65","value":"3.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"37"}],"units":"Participants"}],"title":"Sitting pulse Week 48"}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"104"}],"units":"Participants"}],"description":"Change from baseline is shown as: Percent change from baseline (BL) =((Post BL value - BL value)/ BL value)\\*100","dispersionType":"Standard Deviation","groups":[{"description":"Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 600 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 600 μg for glucose impaired metabolism patients. Mean daily dose category is defined: 600 μg bid group includes all patients whose mean daily dose \\< 1500 μg /day.","id":"OG000","title":"Pasireotide 600 μg"},{"description":"Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg. Mean daily dose category is defined : 900 μg bid group includes all patients whose mean daily dose ≥ 1500 μg /day","id":"OG001","title":"Pasireotide 900 μg"},{"description":"Patients received pasireotide 600 μg or 900 μg BID","id":"OG002","title":"All Patients"}],"paramType":"MEAN","populationDescription":"Number of patients with available data differed at visits","reportingStatus":"POSTED","timeFrame":"Baseline, week 12, 24 and 48","title":"Percent Change in Cushing's Disease Clinical Signs and Symptoms - Pulse","type":"SECONDARY","unitOfMeasure":"percent change in bpm"}